Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical CBD for Post-exercise Recovery
NCT05044936Phase 1Withdrawn
- Sponsor
- The University of New Mexico
- Start
- May 2023
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Zygel in delayed onset muscle soreness (DOMS), sponsored by The University of New Mexico. Primary endpoints: Creatine Kinase at 48 hours, Lactate Dehydrogenase at 48 hours and 5 more. Planned start May 2023; status: withdrawn.
02
Drugs
Zygel
03
Conditions
delayed onset muscle soreness (DOMS)
Beyond the preview
Go deeper on NCT05044936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044936.